

Table SIII. Patient characteristics of bacterial skin infections and *Herpesviridae* infections for biologics for psoriasis

Patient characteristics	Biologics				
	Ustekinumab N = 11,704 ^a	Secukinumab N = 7,454	Etanercept N = 62,737	Infliximab N = 4,274	Adalimumab N = 52,136
<i>Bacterial skin infection</i>	N = 221	N = 87	N = 406	N = 63	N = 409
Age, years, median (IQR)	54 (45; 62)	55 (45; 64)	55 (44.5; 62)	52.5 (44.5; 63.3)	53 (43; 62)
Female sex, n (%)	90 (41.7)	40 (46.5)	197 (52.4)	33 (52.4)	204 (51.6)
Concomitant medication, n (%)					
Antidiabetics	16 (7.2)	5 (5.7)	13 (3.2)	7 (11.1)	44 (10.8)
Antibiotics	21 (9.5)	1 (1.1)	9 (2.2)	2 (3.2)	29 (7.1)
Immunosuppressives (any)	39 (17.6)	12 (13.8)	30 (7.4)	13 (20.6)	50 (12.2)
Methotrexate	15 (6.8)	7 (8)	18 (4.4)	7 (11.1)	23 (5.6)
Prednisone	3 (1.4)	0	4 (1.0)	0	6 (1.5)
<i>Herpesviridae infection</i>	N = 145	N = 65	N = 327	N = 41	N = 347
Age, years, median (IQR)	52 (39; 64)	50 (40; 59.3)	55 (41; 64)	54.5 (38.3; 62.8)	53 (40; 63)
Female sex, n (%)	82 (58.2)	42 (64.6)	187 (63)	20 (51.3)	188 (55)
Concomitant medication, n (%)					
Antidiabetics	2 (1.4)	3 (4.6)	3 (0.9)	0	25 (7.2)
Antibiotics	5 (3.4)	0	6 (1.8)	2 (4.9)	11 (3.2)
Immunosuppressives (any)	17 (11.7)	6 (9.2)	20 (6.1)	9 (22)	36 (10.4)
Methotrexate	7 (4.8)	2 (3.1)	11 (3.4)	9 (22)	13 (3.7)
Prednisone	2 (1.4)	0	2 (0.6)	1 (2.4)	5 (1.4)

^aN indicates the number of individual case safety reports (ICSR) in the WHO database.

IQR: interquartile range.